Side-by-side · Research reference

BronchogenvsCerebrolysin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED16/35 cited

BPhase 3HUMAN-REVIEWED11/65 cited

Bronchogen

Tetrapeptide Bioregulator · Khavinson-School

0.05 ng/mLEffective concentrationZakutskiĭ 2006

60 daysCOPD model durationTitova 2017

30 daysTreatment courseKuzubova 2015

Research models: tissue culture / parenteral

Cerebrolysin

Porcine Brain-Derived Peptide Mix · Phase 3

30 mL/dayStandard doseAfridi 2026 Staszewski 2026

14–21 daysTreatment course

49% vs 35%mRS 0-2 at 12 moStaszewski 2026

IV infusion · 100-250 mL saline · Daily

01Mechanism of Action

Parameter

Bronchogen

Cerebrolysin

Primary target

Bronchial epithelial cellsKuzubova 2015

Multiple neurotrophic pathways — mimics BDNF, NGF, CNTF receptor activation

Pathway

Tissue-specific bioregulation → epithelial cell differentiation → ciliated cell restoration

Cerebrolysin peptides → BDNF/NGF/CNTF receptor binding → TrkB/TrkA/LIFR signaling → neuroprotection, neuroplasticity, synaptogenesis

Downstream effect

Reversal of goblet cell hyperplasia, squamous metaplasia elimination, restoration of ciliated epithelium, normalized secretory IgA and surfactant protein B productionKuzubova 2015 Titova 2017

Reduced apoptosis (Bax ↓, Bcl-2 ↑), suppressed TNF-α inflammation, elevated endogenous BDNF, enhanced synaptic plasticity and motor recovery

Feedback intact?

—

Yes — exogenous peptides do not suppress endogenous neurotrophic factor synthesis

Origin

Synthetic tetrapeptide (Ala-Glu-Asp-Leu) from Khavinson bioregulator framework

Enzymatic breakdown of lipid-free porcine brain proteins → standardized low-MW peptide fraction (<10 kDa) + free amino acids

Antibody development

—

Not reported in human trials; porcine origin theoretically immunogenic but no clinically significant allergic reactions documented

02Dosage Protocols

Parameter

Bronchogen

Cerebrolysin

Effective concentration (culture)

0.05 ng/mLZakutskiĭ 2006

Demonstrated in organotypic tissue culture of bronchial explants.

—

Treatment duration (animal)

1 month (30 days)Kuzubova 2015 Titova 2017

Course duration in rat COPD models.

—

Evidence basis

Animal models (rat) / organotypic cultureTitova 2017 Kuzubova 2015 Zakutskiĭ 2006

No human clinical trials reported in available literature.

Phase 3 RCT + observational

Model system

NO₂-induced COPD (60-day intermittent exposure)Titova 2017

—

Tissue specificity

Selective for bronchopulmonary tissue

Part of Khavinson organ-specific bioregulator series.

—

Standard dose (stroke)

—

30–50 mL / day IVStaszewski 2026 Afridi 2026

Most trials use 30 mL in 100-250 mL saline over 30-60 min.

Lower dose (dementia)

—

10–20 mL / day IV or IMKhatkova 2026

Chronic neurodegenerative conditions; intermittent courses.

High dose (TBI)

—

50 mL / day IVKobayashi 2025

CLINCH trial protocol for intracerebral hemorrhage.

Duration

—

10–21 days (acute); intermittent courses (chronic)

Stroke trials typically 10-14 days; rehabilitation phases may use repeated 10-day courses.

Timing (stroke)

—

Initiate within 12 hrs of symptom onset; up to 6 hrs optimal

Earlier initiation associated with better outcomes.

Adjunct to thrombectomy

—

30-50 mL daily × 10-14 days, starting day of EVT

Propensity-matched data show 12-mo mRS 0-2 improved from 35% to 49%.

Administration route

—

IV infusion (preferred) or IM injection

IV allows higher doses; IM used in outpatient/chronic settings.

04Side Effects & Safety

Parameter

Bronchogen

Cerebrolysin

Animal safety profile

No adverse effects reported in published rat studies

Limited safety data; only animal models available.

—

Human data

Absent — no clinical trials in humans reported

—

Long-term effects

Unknown — maximum study duration 30 days in animals

—

Injection site reaction

—

Mild pain, erythema (IM route)

Infusion reaction

—

Rare: flushing, transient hypotension during rapid IV

Agitation / Restlessness

—

Reported in <5% of patients; typically mild, self-limited

Headache

—

Mild, transient; incidence not significantly elevated vs placeboPatel 2025

Serious adverse events

—

No significant increase vs placebo (RR 1.02, 95% CI 0.87-1.20)

Hemorrhagic transformation

—

Reduced incidence vs control (52% reduction in high-risk post-thrombolysis cohort)Kalinin 2025

Mortality

—

No increase; meta-analysis RR 0.89 (0.68-1.18)

Allergic reaction

—

Rare; porcine origin theoretically immunogenic but clinically insignificant

Seizure risk

—

Not elevated; safe in epilepsy populations

Absolute Contraindications

Bronchogen

—

Cerebrolysin

·Known hypersensitivity to porcine-derived products
·Active seizure disorder (relative — caution advised)

Relative Contraindications

Bronchogen

—

Cerebrolysin

·Severe renal impairment (amino acid load — monitor)
·Pregnancy / lactation (insufficient safety data)

05Administration Protocol

Parameter

Bronchogen

Cerebrolysin

1. Research context only

Bronchogen has been studied exclusively in animal models and organotypic tissue culture. No approved formulation or human administration protocol exists.

Dilute prescribed dose (10-50 mL) in 100-250 mL 0.9% sodium chloride. Use immediately after preparation. Do not mix with other medications in same infusion bag.

2. Animal model protocol

In rat COPD models, tetrapeptide administered for 30-day course following 60-day NO₂ exposure. Route and exact dosing not specified in abstracts.Titova 2017 Kuzubova 2015

Administer over 30-60 minutes. Slower infusion reduces risk of transient hypotension or flushing. Monitor vital signs during first administration.

3. Organotypic culture

Bronchial tissue explants from young (3-week) and aged (18-month) rats cultured in medium containing 0.05 ng/mL bronchogen, demonstrating tissue-specific stimulation.Zakutskiĭ 2006

For 5-10 mL doses: inject deep IM into gluteal or deltoid muscle. Rotate sites if repeated daily. IM preferred for outpatient/chronic use.

4. Khavinson bioregulator tradition

Part of Russian peptide bioregulator framework emphasizing tissue-specific low-dose effects. Typically administered parenterally in related peptides from this series.

Acute stroke: initiate within 6-12 hrs of symptom onset. Daily administration, preferably same time each day. Continue 10-21 days per protocol.

5. Storage

—

Store unopened ampoules at 15-25°C, protected from light. Do not freeze. Use diluted solution immediately; discard unused portion.

6. Co-administration

—

Compatible with standard stroke care (thrombolysis, thrombectomy, antiplatelet/anticoagulant therapy). Does not interfere with reperfusion therapies.

06Stack Synergy

Bronchogen

— no documented stacks

Cerebrolysin

+ Semax

Moderate

View Semax →

Cerebrolysin (multimodal neurotrophic peptide mix) and Semax (ACTH(4-10) analogue) operate through complementary neuroprotective pathways. Cerebrolysin elevates BDNF and suppresses apoptosis/inflammation via TrkB/TrkA signaling, while Semax enhances neuroplasticity through BDNF upregulation and dopaminergic modulation. Combined use in stroke or TBI may amplify anti-apoptotic effects and accelerate cognitive/motor recovery, though no direct RCT data exist for the combination.

Cerebrolysin: 30 mL IV daily × 10-14 days
Semax: 300-600 mcg intranasal BID × 10-14 days
Timing: Concurrent during acute recovery phase
Primary benefit: Enhanced neuroprotection, accelerated motor/cognitive recovery post-stroke or TBI

+ BPC-157

Multi-pathway

View BPC-157 →

Cerebrolysin provides CNS-specific neurotrophic support (BDNF, NGF pathways), while BPC-157 offers systemic tissue repair via angiogenesis (VEGF upregulation) and anti-inflammatory effects. In traumatic brain injury or stroke, Cerebrolysin addresses neuronal survival and synaptic plasticity, whereas BPC-157 may enhance vascular repair and blood-brain barrier integrity. The combination targets both neuronal and vascular compartments of brain injury, though clinical validation is lacking.

Cerebrolysin: 30-50 mL IV daily × 14 days
BPC-157: 250-500 mcg SQ daily × 14-28 days
Timing: Initiate both within 24-48 hrs of injury
Primary benefit: Dual neuronal + vascular repair in TBI or stroke; accelerated functional recovery